Skip to content
zameds

Hydrocortisone, neomycin, phenylephrine, phenylpropanolamine (Nasomixin)

Hydrocortisone, neomycin, phenylephrine, phenylpropanolamine

Sanofi-aventis South Africa (Pty) Ltd

Registration

Applicant
Sanofi-aventis South Africa (Pty) Ltd
Registrations
1

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Nasomixin

EACH 15 ml CONTAINS HYDROCORTISONE A 9 mg NEOMYCIN SULPHATE A EQUIVALENT TO NEOMYCIN 15 mg PHENYLEPHRINE HYDROCHLORIDE A 54 mg PHENYLPROPANOLAMINE HYDROCHLORIDE A 105 mg

Not listedH1422Old MedicineNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S6: Phenylpropanolamine

    • except products registered in terms of the Act, not intended for export and oral preparations and mixtures where the recommended daily dose for adults does not exceed 100 milligrams and for children 6 to 12 years does not exceed 50 milligrams, when in combination with another pharmacologically active substance and intended for the symptomatic relief of nasal and sinus congestion, subject to a maximum pack size of 300 milligrams for adults and 150 milligrams for children, limited to one pack per customer. (S2)

    Consolidated Schedules 06 July 2026, lines 10387 to 10394

  • S4: Neomycin

    • except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

    Consolidated Schedules 06 July 2026, lines 7224 to 7225

  • S4: Phenylephrine

    • when intended for injection
    • except ophthalmic preparations containing 0,2 percent or less. (S0)
    • except for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms containing more than 0,2 percent (S1)

    Consolidated Schedules 06 July 2026, lines 7545 to 7552

  • S2: Phenylpropanolamine

    • contained in products registered in terms of the Act, and not intended for export, unless listed separately in the Schedules,
    • oral preparations and mixtures where the recommended daily dose for adults does not exceed 100 milligrams and for children 6 to 12 years does not exceed 50 milligrams, when in combination with another pharmacologically active substance and intended for the symptomatic relief of nasal and sinus congestion, subject to a maximum pack size of 300 milligrams for adults and 150 milligrams for children, limited to one pack per customer. (S6)

    Consolidated Schedules 06 July 2026, lines 2516 to 2523

  • S1: Phenylephrine

    • when intended for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms containing more than 0,2 percent; (S1)
    • except ophthalmic preparations containing 0,2 percent or less; (S0)
    • except when intended for injection. (S4)

    Consolidated Schedules 06 July 2026, lines 1007 to 1014

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles